On Jul. 9, 2020, Atos announced that the Biocomputing Unit at the Spanish National Center for Biotechnology (CNB), part of the Spanish National Research Council, had begun using Atos supercomputing resource to produce a refined 3D model of the SARS-Cov2 spike protein. By knowing more detail about the structure of this protein, which is the one that the virus uses to enter human cells, researchers can better understand how the virus initiates infection. This important step forward may help in the development of a vaccine.

The model, created at the Biocomputing Unit of CNB-CSIC using 3D cryoelectron microscopy, a complicated structural technique, will enable researchers and scientists to visualize not only the spike glycoprotein but also other SARS-Cov2 proteins. It has been made available to all scientific researchers across the world working on the virus.

Atos is a global leader in digital transformation with 110,000 employees in 73 countries and annual revenue of € 12 billion. European number one in Cloud, Cybersecurity and High-Performance Computing, the Group provides end-to-end Orchestrated Hybrid Cloud, Big Data, Business Applications and Digital Workplace solutions. The Group is the Worldwide Information Technology Partner for the Olympic & Paralympic Games and operates under the brands Atos, Atos|Syntel, and Unify. Atos is a SE (Societas Europaea), listed on the CAC40 Paris stock index.